BC Extra | Dec 27, 2019
Clinical News

Spring Bank’s HBV therapy on hold after signs of liver damage

Spring Bank’s revelation of liver toxicity in chronic HBV patients treated with inarigivir soproxil in a Phase IIb trial sent the company’s shares down 67% Thursday; however, the readout doesn’t necessarily mean that immuno-oncology therapies...
BC Innovations | Oct 15, 2019
Emerging Company Profile

Abalos’ arena: planning to upstage oncolytic viruses

Abalos launched Tuesday with a €12 million ($13.2 million) series A round to advance its arenavirus-based cancer therapies, which offer an alternative to oncolytic viruses, and rely on prolonged immune responses to clear tumors. Boehringer...
BioCentury | Oct 1, 2019
Finance

STING start-up STipe first to emerge from Novo incubator

STipe, the first company out of Novo’s BioInnovation Initiative, raised €20 million ($21.9 million) in a series A round to develop technology designed to improve the therapeutic window of STING modulators in the clinic. Novo...
BioCentury | Jul 31, 2019
Finance

How Wellington closed its largest fund yet at €210M

Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria and Switzerland, helped Wellington Partners raise its largest fund to date. Wellington announced Wednesday the close of Wellington Partners...
BC Week In Review | Jul 13, 2018
Financial News

Forbion raises €270M, surpassing target for fourth fund

Forbion Capital Partners raised €270 million ($317.8 million) toward Forbion IV, surpassing its target of €250 million. The firm said the fund will have a "sharper focus" on biotech investments than Forbion Capital Fund III...
BioCentury | Jul 13, 2018
Finance

Forbion builds immunity

With global investors’ interest in European start-ups rising, Forbion Capital Partners plans to emphasize building new companies from scratch as it invests its fourth fund. The firm hopes that by building strong relationships early in...
BC Extra | Jul 11, 2018
Financial News

Forbion raises €270M, surpassing target for fourth fund

Forbion Capital Partners raised €270 million ($317.8 million) toward Forbion IV, surpassing its target of €250 million ($294.2 million). The firm said the fund will have a "sharper focus" on biotech investments than Forbion Capital...
BC Innovations | Apr 3, 2018
Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
BC Week In Review | Jan 5, 2018
Financial News

Boehringer increases investment fund, expands focus

Boehringer Ingelheim GmbH (Ingelheim, Germany) said on Jan. 3 it added €150 million ($178.1 million) to its Boehringer Ingelheim Venture Fund, boosting its total to €250 million ($296.9 million), and is expanding the fund's investment...
BC Extra | Jan 3, 2018
Financial News

Boehringer Ingelheim enlarges investment fund

Boehringer Ingelheim GmbH (Ingelheim, Germany) added €150 million ($178.1 million) to its Boehringer Ingelheim Venture Fund, boosting its total to €250 million ($296.9 million), and is expanding the fund's investment focus to include regenerative medicine,...
Items per page:
1 - 10 of 29
BC Extra | Dec 27, 2019
Clinical News

Spring Bank’s HBV therapy on hold after signs of liver damage

Spring Bank’s revelation of liver toxicity in chronic HBV patients treated with inarigivir soproxil in a Phase IIb trial sent the company’s shares down 67% Thursday; however, the readout doesn’t necessarily mean that immuno-oncology therapies...
BC Innovations | Oct 15, 2019
Emerging Company Profile

Abalos’ arena: planning to upstage oncolytic viruses

Abalos launched Tuesday with a €12 million ($13.2 million) series A round to advance its arenavirus-based cancer therapies, which offer an alternative to oncolytic viruses, and rely on prolonged immune responses to clear tumors. Boehringer...
BioCentury | Oct 1, 2019
Finance

STING start-up STipe first to emerge from Novo incubator

STipe, the first company out of Novo’s BioInnovation Initiative, raised €20 million ($21.9 million) in a series A round to develop technology designed to improve the therapeutic window of STING modulators in the clinic. Novo...
BioCentury | Jul 31, 2019
Finance

How Wellington closed its largest fund yet at €210M

Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria and Switzerland, helped Wellington Partners raise its largest fund to date. Wellington announced Wednesday the close of Wellington Partners...
BC Week In Review | Jul 13, 2018
Financial News

Forbion raises €270M, surpassing target for fourth fund

Forbion Capital Partners raised €270 million ($317.8 million) toward Forbion IV, surpassing its target of €250 million. The firm said the fund will have a "sharper focus" on biotech investments than Forbion Capital Fund III...
BioCentury | Jul 13, 2018
Finance

Forbion builds immunity

With global investors’ interest in European start-ups rising, Forbion Capital Partners plans to emphasize building new companies from scratch as it invests its fourth fund. The firm hopes that by building strong relationships early in...
BC Extra | Jul 11, 2018
Financial News

Forbion raises €270M, surpassing target for fourth fund

Forbion Capital Partners raised €270 million ($317.8 million) toward Forbion IV, surpassing its target of €250 million ($294.2 million). The firm said the fund will have a "sharper focus" on biotech investments than Forbion Capital...
BC Innovations | Apr 3, 2018
Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
BC Week In Review | Jan 5, 2018
Financial News

Boehringer increases investment fund, expands focus

Boehringer Ingelheim GmbH (Ingelheim, Germany) said on Jan. 3 it added €150 million ($178.1 million) to its Boehringer Ingelheim Venture Fund, boosting its total to €250 million ($296.9 million), and is expanding the fund's investment...
BC Extra | Jan 3, 2018
Financial News

Boehringer Ingelheim enlarges investment fund

Boehringer Ingelheim GmbH (Ingelheim, Germany) added €150 million ($178.1 million) to its Boehringer Ingelheim Venture Fund, boosting its total to €250 million ($296.9 million), and is expanding the fund's investment focus to include regenerative medicine,...
Items per page:
1 - 10 of 29